Research programme: anti-HGF monoclonal antibodies - Amgen

Drug Profile

Research programme: anti-HGF monoclonal antibodies - Amgen

Alternative Names: 2.12.1; 2.4.4; Anti-HGF(hu)mAb 2.12.1; Anti-HGF(hu)mAb 2.4.4; Hepatocyte growth factor inhibitors - Amgen

Latest Information Update: 30 Mar 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Monoclonal antibodies
  • Mechanism of Action Hepatocyte growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 11 Sep 2008 Preclinical development is ongoing in the US
  • 02 May 2006 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top